Comparison of selected metrics for XGBoost and LR (baseline) on the defined experiments, see Fig 3. The best-performing metric values are represented in bold font.
Tamoxifen (TAM), a selective oestrogen receptor modulator, is one of the most used treatments in oestrogen receptor-positive (ER+) early and metastatic breast cancer (BC) patients. The response to TAM
Congestive heart failure (CHF) is an incurable disease where a key objective of the treatment is to maintain the patient’s quality of life (QoL) as much as possible. A model that predicts health-relat
